Navigation Links
A 'Must Read' for Breast Cancer Patients
Date:12/18/2007

SAN JOSE, Calif., Dec. 18 /PRNewswire/ -- Patent 7,309,486 issued on 12/18/07 to NexGen Biomedical, Inc. founder Mark Zamoyski of San Jose, California discloses a better way of using Genentech's drug Herceptin(R) against breast cancer. The patent discloses that today's practice of concurrent administration of Herceptin(R) with conventional phase specific chemotherapy results in antagonistic action between the two classes of drugs. In later stage cancers, these protocols only increase median survival by several months.

Patent 7,309,486 discloses novel protocols that allow the two classes of chemotherapeutics to function synergistically. The protocols are designed to provide a way of holding the cancer in check indefinitely.

All proliferating cells progress through 4 distinct phases termed G1, S, G2, and M. "S-Phase cytotoxics, such as Pfizer's Camptosar(R) or Eli Lilly's Gemzar(R), are capable of killing virtually all cells that are in the S-Phase, however, in the best case, only around one third of cancer cells are typically in the S-Phase during chemotherapy," explains Mark Zamoyski, the inventor. "The patented protocols boost the number of cells in the S-Phase by exploiting the cancer's unique mutation profile to establish a "road block" to aggregate a large number of cancer cells at a point prior to the S-Phase, the road block is then removed to allow the wave of cancer cells to enter the S-Phase during the administration time of the S-Phase cytotoxic chemotherapy, and then the road block is reestablished to start aggregating surviving cancer cells for the next administration of S-Phase cytotoxic chemotherapy."

The abstract contained in the patent has been incorrectly truncated and a correct synopsis of the patent is available at http://www.nexgen.biz under Cell Cycle Synchronous Chemotherapy.


'/>"/>
SOURCE NexGen Biomedical, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Middle East Pharma Manufacturing/Biotech is Ready to Boom
2. Digital Healthcare Announces Cincinnati Eye Institute is Latest Retasure Reading Center
3. Significant Progress Made in Nations Preparedness to Respond to Public Health Emergencies; But Gaps in Critical Areas Threaten Overall Readiness
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
6. Imaging Diagnostic Systems New Laser Breast Imaging Scanner Introduced in Malaysia
7. NeoMatrix Announces Additional Funding for Breakthrough Breast Cancer Screening Test
8. Largest Asian Cancer Hospital to Evaluate New CT Laser Breast Imaging System
9. Cellumen Establishes Collaboration in Breast Cancer Patient Stratification
10. Celebrities and Notables From the Worlds of Film, Television, Music and Sports Join Lifetime Televisions 13th Annual Multi-Platform Stop Breast Cancer For Life Campaign
11. Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016  Global demand for enzymes is ... 2020 to $7.2 billion.  This market includes enzymes ... products, biofuel production, animal feed, and other markets) ... biocatalysts). Food and beverages will remain the largest ... consumption of products containing enzymes in developing regions.  ...
(Date:6/27/2016)... ... June 27, 2016 , ... Newly ... technologies, services and solutions to the healthcare market. The company's primary focus is ... manufacturing, sales and marketing strategies that are necessary to help companies efficiently bring ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
(Date:4/19/2016)... UAE, April 20, 2016 The ... as a compact web-based "all-in-one" system solution for all ... fingerprint reader or the door interface with integration authorization ... access control systems. The minimal dimensions of the access ... into the building installations offer considerable freedom of design ...
(Date:4/14/2016)... , April 14, 2016 ... and Malware Detection, today announced the appointment of ... the new role. Goldwerger,s leadership appointment comes ... the heels of the deployment of its platform at ... behavioral biometric technology, which discerns unique cognitive and physiological ...
Breaking Biology News(10 mins):